A report of two EML4-ALK+ NSCLC cases under TKI further highlighted the predictive value of CTC liquid biopsy, which allowed to differentiate the two patients in their clinical course: re-emergence of CTCs during follow-up correlated with disease progression [115]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.